New Drug Application Approved For Once-Daily Allegra-D Formulation Using aaiPharma Inc.'s (AAII) Development Expertise 
10/19/2005 5:11:57 PM

aaiPharma Inc. (NASDAQ: AAII) today confirmed the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for Aventis' new Allegra-D 24 Hour tablets (fexofenadine HCl 180 mg / pseudoephedrine HCl 240 mg), a formulation developed with aaiPharma and Osmotica Pharmaceutical.